Tradegate
14.04.26 | 15:20
2,750 Euro
+0,07 % +0,002
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,740 | 2,794 | 14.04. | |
| 2,740 | 2,794 | 14.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | HANSA BIOPHARMA AB: Hansa Biopharma to host Q1 2026 interim results conference call | 2 | Cision News | ||
| 26.03. | Hansa Biopharma AB: Hansa Biopharma publishes 2025 Annual and Sustainability Reports | 364 | PR Newswire | LUND, Sweden, March 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025.
Peter... ► Artikel lesen | |
| 13.03. | HANSA BIOPHARMA AB: Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science | 1 | Cision News | ||
| 10.03. | HANSA BIOPHARMA AB: Hansa Biopharma participating at DNB Carnegie Healthcare Conference 2026 | 1 | Cision News | ||
| 09.03. | HANSA BIOPHARMA AB: Hansa Biopharma participating at LSX Investival Showcase USA | 1 | Cision News | ||
| HANSA BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 06.03. | HANSA BIOPHARMA AB: Hansa Biopharma participating at Leerink Global Healthcare Conference | 1 | Cision News | ||
| 05.03. | Hansa Biopharma AB: PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026 | 495 | PR Newswire | If approved, imlifidase will be the first treatment
to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma... ► Artikel lesen | |
| 23.02. | HANSA BIOPHARMA AB: Hansa Biopharma presenting at TD Cowen's 46th Annual Health Care Conference | 1 | Cision News | ||
| 18.02. | Hansa Biopharma AB: Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA | 197 | GlobeNewswire (Europe) | Lund, Sweden, 18 February 2026. Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted... ► Artikel lesen | |
| 11.02. | Hansa Biopharma reports Q4 results | 17 | Seeking Alpha | ||
| 11.02. | Hansa Biopharma AB: Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results | 422 | PR Newswire | Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024.
Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting... ► Artikel lesen | |
| 26.01. | HANSA BIOPHARMA AB: Hansa Biopharma to host Year-end report 2025 conference call | 4 | Cision News | ||
| 22.01. | Hansa Biopharma AB: Hansa Biopharma has won the 2025 SwedenBIO Award | 394 | PR Newswire | LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The... ► Artikel lesen | |
| 07.01. | Wedbush initiates coverage on Hansa Biopharma stock with Outperform rating | 1 | Investing.com | ||
| 19.12.25 | Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation | 870 | PR Newswire | The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types... ► Artikel lesen | |
| 19.12.25 | HANSA BIOPHARMA AB: Hansa Biopharma presenting at 44th Annual J.P. Morgan Healthcare Conference | 2 | Cision News | ||
| 16.12.25 | Hansa Biopharma AB: Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease | 321 | GlobeNewswire (Europe) | Lund, Sweden, 16 December 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that GOOD-IDES-02, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM)... ► Artikel lesen | |
| 15.12.25 | Hansa Biopharma AB: Hansa Biopharma announce changes to strengthen European and International organisation | 239 | GlobeNewswire (Europe) | Lund, Sweden, December 15, 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced a reorganization of its European and International Commercial and Medical Affairs operations, effective... ► Artikel lesen | |
| 13.11.25 | HANSA BIOPHARMA AB: Hansa Biopharma presenting at Jefferies Global Healthcare Conference and DNB Carnegie's 16th Annual Nordic Healthcare Conference | 2 | Cision News | ||
| 05.11.25 | HANSA BIOPHARMA AB: Hansa at Truist Securities, Stifel, and SEB Healthcare conferences | 5 | Cision News |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,55 | +1,58 % | BioNTech SE: BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs | Trastuzumab Pamirtecan, ein innovativer gegen HER2 gerichteter Antikörper-Wirkstoff-Konjugat-Kandidat, erreichte den primären Wirksamkeitsendpunkt in einer Phase-2-Kohorte bei stark vorbehandelten Patientinnen... ► Artikel lesen | |
| EVOTEC | 5,390 | +14,68 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| MODERNA | 44,855 | +4,07 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| NOVAVAX | 7,100 | +3,05 % | Activist investor revives campaign to overhaul Novavax board | ||
| HEIDELBERG PHARMA | 2,780 | +2,58 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,475 | +4,01 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 638,00 | +0,52 % | Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU | DJ Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU
Von Colin Kellaher
DOW JONES--Regeneron Pharmaceuticals und Sanofi haben für ihren Blockbuster-Entzündungshemmer Dupixent... ► Artikel lesen | |
| OCUGEN | 1,512 | -0,40 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,940 | +0,97 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| BIONXT SOLUTIONS | 0,306 | +2,68 % | BioNxt sichert sich einheitliches europäisches Patent für seine sublinguale Cladribin-ODF-Plattform in 18 Ländern | VANCOUVER, BC / ACCESS Newswire / 7. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives Biowissenschaftsunternehmen, das
sich... ► Artikel lesen | |
| MAINZ BIOMED | 0,607 | +20,07 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| INFLARX | 0,971 | +6,12 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| VIVORYON THERAPEUTICS | 1,360 | 0,00 % | Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference | Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
Halle (Saale) / Munich, Germany, April 9, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon),... ► Artikel lesen |
HANSA BIOPHARMA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,750 Euro und damit +0,07 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HANSA BIOPHARMA AB finden Sie auf Wallstreet Online.